UBS analyst Jonathan Yong nearly doubled the price target on Clover Health Investments to $4.75 from $2.75 while maintaining a Neutral rating, reflecting improving confidence in the company's operating outlook. Earlier, Canaccord raised its target to $4.20 from $3.20 with a Buy rating, citing strong April and May performance and improving managed care conditions. Clover Health, a Medicare Advantage insurer and healthcare technology company, has a projected five-year EPS growth rate of 51.31%.
Clover Health Investments CorpUBS and Canaccord raised price targets, reflecting improved operating outlook and strong performance.
UBS Group AG